

STEMCELLS INC
Form 8-K
October 26, 2004

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 25, 2004

StemCells, Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-19871

94-3078125

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

3155 Porter Drive, Palo Alto, California

94304

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: **(650) 475-3100**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-
-

TABLE OF CONTENTS

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITIONS.

ITEM 8.01 OTHER EVENTS.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

SIGNATURES

EXHIBIT 1.1

EXHIBIT 10.1

EXHIBIT 99.1

EXHIBIT 99.2

Table of Contents

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITIONS.

On October 26, 2004, StemCells, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2004. The full text of the press release is attached hereto as Exhibit 99.1.

ITEM 8.01 OTHER EVENTS.

In connection with filing this current report on Form 8-K, the Company is filing a prospectus supplement to its existing shelf registration statement on Form S-3 (File No. 333-83992) in connection with an offering by the Company of shares of its common stock. The Company has executed an agency agreement, dated as of October 25, 2004, with C.E. Unterberg, Towbin, LLC and Shoreline Pacific, LLC, its agents for this offering.

The purpose of this report is to file as exhibits, in connection with this offering, the agency agreement by and between the Company and its agents for the offering and the form of investor purchase agreement.

A copy of the press release issued by the Company in connection with the above described offering is attached hereto as Exhibit 99.2.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

| | |
|--------------|--|
| Exhibit 1.1 | Agency Agreement dated October 25, 2004 by and among StemCells, Inc., C.E. Unterberg, Towbin, LLC and Shoreline Pacific, LLC |
| Exhibit 10.1 | Form of Investor Purchase Agreement |
| Exhibit 99.1 | Press release |
| Exhibit 99.2 | Press release |

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STEMCELLS, INC.

By: /s/ Martin McGlynn
Martin McGlynn
President and Chief Executive Officer

Date: October 26, 2004

Table of Contents

EXHIBIT INDEX

| | |
|--------------|--|
| Exhibit 1.1 | Agency Agreement dated October 25, 2004 by and among StemCells, Inc., C.E. Unterberg, Towbin, LLC and Shoreline Pacific, LLC |
| Exhibit 10.1 | Form of Investor Purchase Agreement |
| Exhibit 99.1 | Press release |
| Exhibit 99.2 | Press release |